Exclusive | I went through the wringer to get menopause drugs — what we need as FDA changes ‘black box’ warning

The Biden administration and FDA moved to ask drugmakers to remove long-standing “black box” warnings on hormone replacement therapy (HRT), calling the labels misleading after decades of caution stemming from a 2002 study; HRT use in the U.S. fell from about 27% in 1999 to under 5% by 2020. Newer, not-yet-peer-reviewed research presented at a 2025 meeting reported a 60% lower breast-cancer rate and fewer cardiovascular events for women who begin HRT in perimenopause, and clinicians and patients say removal of the warning could reduce stigma and treatment barriers; the article illustrates access frictions through one patient’s experience with insurer age limits and out-of-pocket costs before receiving effective transdermal estradiol and progesterone via telehealth. For investors, the policy shift signals a potential increase in demand for HRT products and menopause-focused telehealth services, a narrowing of regulatory overhang for manufacturers, and pressure on payers to revise coverage—although broad uptake will depend on re-education of clinicians and patients and further confirmatory evidence.

Analysis

The Department of Health and Human Services announced it will ask drugmakers to remove the FDA's long-standing "black box" warning on hormone replacement therapy (HRT), calling the label misleading and rooted in outdated science; the warning originated after a 2002 study and HRT use in the U.S. fell from roughly 27% in 1999 to under 5% by 2020. HHS Secretary Robert F. Kennedy Jr. framed the change as a return to evidence-based medicine, creating a regulatory tailwind for HRT manufacturers and clinicians focused on menopause care.

New data presented at the Menopause Society’s 2025 meeting — not yet peer-reviewed — reported a 60% lower breast-cancer rate and fewer cardiovascular events for women who start HRT in perimenopause, supporting clinicians who have criticized the black-box label. The article illustrates material access frictions: a patient faced >$1,200 out-of-pocket costs for Prempro, insurer age-based denials for transdermal patches (approval denied until age 49), and ultimately obtained effective therapy through a telehealth menopause specialist, with rapid symptom relief.

Market signals show moderately positive sentiment (0.45) but modest immediate market-impact (0.3), implying regulatory relief reduces an overhang but does not guarantee rapid uptake. Investors should balance upside from potential demand growth for HRT drugs, transdermal systems and menopause-focused telehealth against key risks: the 2025 study is not peer-reviewed, payer coverage and prior-authorization rules remain significant, and widespread clinician/patient re-education will take time.

Key Decisions for Investors

• Consider modest, targeted exposure to manufacturers of HRT formulations and producers of transdermal delivery systems as regulatory risk diminishes, but size positions conservatively until sales and coverage trends emerge
• Monitor publication and peer review of the 2025 Menopause Society data and formal FDA guidance closely; treat the headline benefits as provisional until replicated in peer-reviewed studies
• Track payer behavior and reimbursement signals (age limits, prior-authorization frequency, formulary placement) as primary gating factors for uptake and revenue realization
• Assess specialist telehealth and digital menopause-care platforms as tactical beneficiaries for patient acquisition and insurer navigation, while maintaining hedges until early commercial traction is visible